SK Plasma, Janssen Korea sign sales, distribution agreement

SK Plasma Co. Ltd., a South Korean company specializing in the production of plasma derivatives from human plasma, is expanding its product portfolio to establish itself as a pharmaceutical company focused on rare and difficult-to-treat diseases.

The company announced on Monday that it has entered into an exclusive domestic sales agreement with Janssen Korea for Dacogen (active ingredient: Decitabine), a treatment for myelodysplastic syndrome and acute myeloid leukemia.

The signing ceremony was attended by SK Plasma CEO Kim Seung-joo and Janssen Korea CEO Cherry Huang. Under the terms of the agreement, SK Plasma will be responsible for the domestic distribution and marketing of Dacogen, while Janssen Korea will handle production and supply.

Dacogen injection, to be introduced by SK Plasma, is an intravenous prescription anti-cancer drug used to treat patients with myelodysplastic syndrome and acute myelogenous leukemia.

After the reimbursement standard for myelodysplastic syndrome was established in 2008, Dacogen injection expanded its coverage to include acute myeloid leukemia patients in 2013 and 2023.

"We will continue to enhance our product line for rare and intractable diseases to improve the treatment options and quality of life for patients with rare conditions," said SK Plasma CEO Kim Seung-joo.

Write to Jeong Min Nam at peux@hankyung.com